

## Special Issue

# New Strategies for the Treatment of Melanoma and Non-Melanoma Skin Cancer

### Message from the Guest Editors

Since nivolumab became available in clinical practice in 2014, the treatment landscape for skin malignancies has undergone dramatic advancements. Anti-PD-1 antibodies have significantly transformed the treatment of many cancers, including melanoma. Around the same time, the development of molecularly targeted drugs for melanoma was also underway. Based on various clinical trial results, Western countries recommend prioritizing immunotherapy as the first-line treatment for unresectable melanoma, with molecularly targeted therapy used sequentially. However, in East Asian melanoma patients, the efficacy of anti-PD-1 antibodies appears to differ from that observed in Western populations, with lower response rates observed. While clinical trials in Japan are evaluating the effects of anti-PD-1 antibodies on non-melanoma skin cancers, the therapeutic efficacy of immunotherapy for cutaneous squamous cell carcinoma has been found to be lower compared to reports from overseas. This Special Issue discusses the racial differences in the effectiveness of immunotherapy—centered on anti-PD-1 antibodies—from the perspectives of both basic research and clinical studies.

### Guest Editors

Prof. Dr. Yoshihide Asano

Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 Seiryō-Machi, Aoba-Ku, Sendai 980-8574, Japan

Dr. Taku Fujimura

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan

### Deadline for manuscript submissions

30 June 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/233293](https://mdpi.com/si/233293)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)